Clinical trials: Prevention of Heart Disease
Stroke, Prevention and Control
An Observational Cross-sectional Study Evaluating the Sociodemographic and Clinical Characteristics of Patients Diagnosed With NVAF With a Risk of Stroke or Systemic Embolism, Who Are on Treatment to Adequately Control Their Coagulation and Treated in Primary Care Centres
describe the sociodemographic and clinical characteristics of patients diagnosed with non-valvular atrial fibrillation (NVAF) at risk of stroke or systemic embolism on anticoagulant therapy who have changed their therapeutic…
- Conditions
- Stroke, Prevention and Control, Atrial Fibrillation
- Trial name
- SILVER-AP (NCT02470767)
- Testing
- Direct Oral Anticoagulant (DOAC)
- Where
- Spain
- Volunteers
- 792 people
- Sponsor
- Bayer
Hemorrhage, Atrial Fibrillation, Postoperative
Prevention of Retained-Blood Outcomes With Active Clearance Technology
Postoperative bleeding is a common consequence after heart surgery which can significantly impact outcomes and costs . When bleeding occurs, reliable postoperative blood evacuation of the pleural, mediastinal and pericardial…
- Trial name
- NCT02145858
- Testing
- Blood drainage post cardiac surgery using PleuraFlow System
- Where
- 2 sites in United States
- Volunteers
- 891 people
- Sponsor
- ClearFlow, Inc.
Atrial Fibrillation
Vernakalant (Oral) Prevention of Atrial Fibrillation Recurrence Post-Conversion Study
To evaluate the safety, tolerability and efficacy of 3 doses of vernakalant (oral) (150 mg, 300 mg and 500 mg b.i.d.) administered for up to 90 days in subjects with sustained symptomatic atrial fibrillation (AF duration > 72…
- Trial name
- NCT00526136
- Testing
- Vernakalant (oral)
- Where
- 152 sites in Australia, Belgium and 22 more
- Volunteers
- 735 people
- Sponsor
- Advanz Pharma
Myocardial Infarction, Cardiovascular Death
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
This study is being carried out to see if a new drug called ticagrelor given twice daily in addition to the ASA therapy decreases the frequency of cardiovascular events (e.g., death from heart disease, heart attack, or stroke).
- Conditions
- Myocardial Infarction, Cardiovascular Death, Atherothrombosis, Stroke
- Trial name
- PEGASUS (NCT01225562)
- Testing
- Ticagrelor 90 mg, Ticagrelor 60 mg
- Where
- 826 sites in United States, Argentina and 29 more
- Volunteers
- 21,379 people
- Sponsor
- AstraZeneca
Acute Kidney Injury
Safety & Efficacy of BCT197 in Patients Undergoing Cardiac Surgery
This study will assess the safety and efficacy of BCT197 on acute kidney injury in patients undergoing cardiac surgery with cardiopulmonary bypass.
- Trial name
- NCT01336959
- Testing
- BCT197 Part A, BCT197 Part B
- Where
- 13 sites in United States, Israel and 1 more
- Volunteers
- 91 people
- Sponsor
- Mereo BioPharma
Hyperkalemia, Heart Failure
Evaluation of Patiromer in Heart Failure Patients
The purpose of this study was to assess the effects of patiromer on serum potassium participants with heart failure. This study also assessed the safety and tolerability of patiromer in participants with heart failure.
- Trial name
- PEARL-HF (NCT00868439)
- Testing
- patiromer
- Where
- 33 sites in United States, Czechia and 5 more
- Volunteers
- 120 people
- Sponsor
- Relypsa, Inc.
Acute Coronary Syndrome
Prevention of Cardiovascular Events by Antiplatelet Agents After Acute Coronary Syndrome
Prevention of cardiovascular events by antiplatelet agents after acute coronary syndrome
- Trial name
- AReMIS (NCT01952392)
- Where
- France
- Volunteers
- 4,992 people
- Sponsor
- AstraZeneca
Sudden Cardiac Death
Assessment of Primary Prevention Patients Receiving An ICD - Systematic Evaluation of ATP
The primary objective is to understand the role of antitachycardia pacing (ATP) in primary prevention patients indicated for implantable cardioverter-defibrillator (ICD) therapy and programmed according to current guidance of…
- Trial name
- APPRAISE ATP (NCT02923726)
- Testing
- Arm 1 (ATP+Shock), Arm 2 (shock only)
- Where
- 134 sites in United States, Austria and 6 more
- Volunteers
- 2,692 people
- Sponsor
- Boston Scientific Corporation
Cardiac Surgery, Coronary Artery Bypass
An Trial of Two Dosing Regimens of AP214 for the Prevention of Kidney Injury in Patients Undergoing Cardiac Surgery
This study investigates the effect of two dose-levels of AP214 on the prevention of (acute) kidney injury after cardiac surgery.
- Conditions
- Cardiac Surgery, Coronary Artery Bypass, Aortic Aneurysm, Valve Surgery
- Trial name
- NCT01256372
- Testing
- AP214
- Where
- Denmark
- Volunteers
- 77 people
- Sponsor
- Action Pharma A/S
Atrial Fibrillation
Real-world Comparative Effectiveness of Apixaban Versus Vitamin K Antagonist
To obtain a better understanding on the comparative effectiveness of apixaban versus VKA (Vitamin K antagonist) for stroke prevention in patients with NVAF (Non-valvular atrial fibrillation) in a real-life setting.
- Trial name
- PIXI-F (NCT02687854)
- Testing
- Apixaban, Vitamin K antagonist
- Where
- United States
- Volunteers
- 18,591 people
- Sponsor
- Bayer
Fibrillation, Atrial
Prevention Of Recurrence Of Atrial Fibrillation
The purpose of this study is to determine whether the study drug is effective in preventing the recurrence of atrial fibrillation (an abnormal heart rhythm).
- Trial name
- NCT00041496
- Testing
- SB-207266
- Volunteers
- 520 people
- Sponsor
- GlaxoSmithKline
Atrial Fibrillation
Dronedarone Pattern of Use in Patients Scheduled for Elective Cardioversion (ELECTRA)
Primary Objective: To determine whether daily administration of dronedarone started 5-7 days before cardioversion is superior to dronedarone started only after cardioversion with respect to the absence of symptomatic, ECG…
- Trial name
- NCT01026090
- Testing
- Dronedarone
- Where
- 43 sites in Canada
- Volunteers
- 292 people
- Sponsor
- Sanofi
Acute Coronary Syndrome
Study Evaluating Safety, Tolerability and Efficacy of YM150 in Subjects With Acute Coronary Syndromes
The purpose of this study is to evaluate the safety and efficacy of various doses of YM150 (the experimental drug) in the prevention of ischemic vascular events in subjects with recent acute coronary syndromes.
- Trial name
- RUBY-1 (NCT00994292)
- Testing
- YM150
- Where
- 131 sites in Argentina, Australia and 19 more
- Volunteers
- 1,276 people
- Sponsor
- Astellas Pharma Europe B.V.
Turner's Syndrome
Growth Hormone Treatment for the Prevention of Short Stature in Young Girls With Turner Syndrome Before the Age of 4 Years
The objective of this study is to evaluate the efficacy and safety of recombinant human growth hormone (r-hGH) treatment in girls with Turner Syndrome under the age of 4 years.
- Trial name
- NCT01066052
- Testing
- r-hGH
- Where
- France
- Volunteers
- 115 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Cardiovascular Disease, Colorectal Cancer
Study to Evaluate How Patients Regard the Benefits and Risks of Low-dose Aspirin for the Prevention of Heart and Blood Vessels Disease and for the Prevention of Cancer of the Colon and Rectum
Research shows that low-dose Aspirin prevents diseases of heart and blood vessels as well as cancer of the colon and rectum and it is also associated with risk of bleeding.
- Trial name
- NCT03603366
- Testing
- Acetylsalicylic acid (Aspirin, BAYE4465)
- Where
- Italy
- Volunteers
- 1,028 people
- Sponsor
- Bayer
Cardiovascular Disease
Pharmacodynamic Trial, of Slow Release ASA, in Platelet Functionalism, a Long Term Treatment Period
Evaluation of the pharmacodynamic profile (antiaggregant profile, balance of prostanoids and nitric oxid) of a ASA-SR (slow-release)formulation in comparison with a ASA NR (normal release), 150 mg, during 12 months of treatment.
- Trial name
- NCT00501254
- Testing
- Slow release acetyl salicylic acid, Antithrombotic effect
- Where
- Spain
- Volunteers
- 100 people
- Sponsor
- Rottapharm Spain
Prevention of Thromboembolic Events, Atrial Fibrillation
An Observational Study (Called RETAF-PS) Using a Patient Survey to Learn More About Treatment Outcomes in Patients With Irregular and Often Rapid Heartbeat (Atrial Fibrillation) Treated With Apixaban in a Real World Setting
This is an observational study in which data from people with atrial fibrillation who received or are currently receiving the drug apixaban to prevent thromboembolic events (blood clots that travel through the blood stream to…
- Trial name
- NCT05471830
- Testing
- Apixaban
- Where
- United States
- Volunteers
- 600 people
- Sponsor
- Bayer
Atrial Fibrillation, Atrial Flutter
A Trial With Dronedarone to Prevent Hospitalization or Death in Patients With Atrial Fibrillation
To assess the efficacy of dronedarone in preventing cardiovascular hospitalization or death from any cause in a population of high-risk patients with atrial fibrillation/atrial flutter (AF/AFL).
- Trial name
- ATHENA (NCT00174785)
- Testing
- dronedarone (SR33589)
- Where
- 37 sites in United States, Argentina and 35 more
- Volunteers
- 4,628 people
- Sponsor
- Sanofi
Myocardial Infarction, Stroke (Including Ischaemic Stroke and Transient Ischaemic Attack)
Study to Gather Information to What Extent Patients Follow the Treatment Regimen of Low-dose Aspirin for Primary and Secondary Prevention of Diseases of the Heart and Blood Vessels
This study aims to gather information to what extent patients follow the treatment regimen of low-dose aspirin for primary and secondary prevention of diseases of the heart and blood vessels.
- Conditions
- Myocardial Infarction, Stroke (Including Ischaemic Stroke and Transient Ischaemic Attack), Unstable Angina, Angina
- Trial name
- PALACE (NCT04097912)
- Testing
- Acetylsalicylic Acid (Aspirin, BAYE4465)
- Where
- 2 sites in Germany, United Kingdom
- Volunteers
- 99,999 people
- Sponsor
- Bayer
Atrial Fibrillation
Efficacy and Safety of Rivaroxaban for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation
This is a clinical study evaluating the efficacy and safety of rivaroxaban for stroke prevention in patients with atrial fibrillation (originally described in Japanese).
- Trial name
- NCT00494871
- Testing
- Rivaroxaban (Xarelto, BAY59-7939), Warfarin
- Where
- 165 sites in Japan
- Volunteers
- 1,280 people
- Sponsor
- Bayer